A Prospective Multicenter Observational Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 103
- 主要终点
- Number of patients with complete remission
研究概览
简要总结
The purpose of this study is to evaluate the effectiveness and safety of decitabine (Dacogen) intravenous injection in patients with Myelodysplastic Syndrome.
详细描述
This is a prospective (in which the patients are first identified and then followed forward as time passes), multi-center (study conducted at multiple sites), observational study (a scientific study to make a clear and easy understanding of the cause and effect relationship) to evaluate the effectiveness and safety information of a 5 day decitabine (Dacogen) regimen in patients with Myelodysplastic Syndrome. This study consist of 3 phases; pre-treatment phase, treatment phase and end of treatment (Day 28~61 after last administration of Dacogen). The patients will receive decitabine intravenous injection 20 mg/m2 one hour once daily for 5 consecutive days for every 4 weeks. Safety evaluations including adverse events and clinical laboratory tests and will be evaluated with adverse events reported for the period ranging from informed consent and during the study to the end of treatment visit including 56 days (8 weeks) after the last administration of the clinical study treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with (primary or secondary) Myelodysplastic Syndrome including chronic myelomonocytic leukemia (CMML) with an International Prognostic Scoring System more than or equal to Interferon-1
- •Patients who have never treated with hypomethylating agent (azacitidine and decitabine)
- •Female patients who are postmenopausal or received contraceptive operation or refrain from sexual relations.
- •Women of childbearing potential should conduct an effective method of birth control as defined in protocol, in case of male patients who will not have a baby within 2 months after the completion of decitabine therapy
排除标准
- •Patients diagnosed with acute myelogenous leukemia (bone marrow stem cell counts exceeding 20 %) or other progressive malignant diseases
- •Patients with active infection of virus or bacteria
- •Patients who used to be treated with azacitidine or decitabine
- •Patients who are hypersensitive to excipients of decitabine
- •Patients who are pregnant and breast-feeding
研究组 & 干预措施
Decitabine
干预措施: No intervention (Drug)
结局指标
主要结局
Number of patients with complete remission
时间窗: Up to 61 days
The complete response includes the evaluations of Bone marrow aspiration and biopsy (less than or equal to 5 percents myeloblast), persistent dysplasia and peripheral blood.
Number of patients with partial remission
时间窗: Up to 61 days
The partial response includes all complete remission evaluating parameters with the exception of bone marrow blasts are decreased by more than or equal to 50 percents over pretreatment but still more than 5 percents and cellularity (the state of a tissue or other mass as regards the number of its constituent cells) and morphology (examination of structure)
Number of patients with hematological improvement
时间窗: Up to 61 days
Response rate
时间窗: After 4 cycles and end of treatment
Response rate is the combination of complete remission, partial remission and hematological improvement and performed according to the response criteria of 'International Working Group 2006' which is standardized criteria for assessing response are essential to ensure comparability among clinical trials for patients with MDS.
次要结局
- Cytogenetic response rate(Up to 61 days)
- Overall survival rate(Up to 61 days)
- Time to acute myeloid leukemia evolution(Up to 61 days)
- Number of patients with progression-free survival status(Up to 61 days)
- Number of patients with adverse event(Up to 61 days)